DOCSLIB.ORG

Download VCC Annual Report 2020-21

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download VCC Annual Report 2020-21 annual report 2020–2021 Vice-Chancellor’s welcome There have not been many constants in Last spring we felt very fortunate to have the two years since we last met in person. the long Easter break to plan for Trinity It has been a time of ever changing rules, term, never imagining that we would still restrictions, adaptations and guidance. be adapting to the pandemic in Michaelmas, But there have been some constants: your Hilary and another Trinity term. Each unwavering support for our University term has been different. Last Trinity term and the gratitude of my colleagues and I we moved all teaching and assessment for your generosity. online and sent almost all students home. In Michaelmas term we welcomed our Philanthropy has played a pivotal role in largest student cohort ever and taught them the evolution of Oxford over the centuries, both online and in person. Hilary term was as the names on so many of our colleges, different again, with many students here but our programmes, and our buildings very little face to face teaching permitted attest. This has continued throughout the and, as I write, we await guidance on how pandemic. Last spring we announced an many of our students will be permitted extraordinarily generous gift of £80 million to return for Trinity term. Throughout, from the Reuben Foundation which will the colleges and the University have worked One of the many lessons of enable us to create the first new college together like never before, ensuring the in 30 years. Reuben College will be the pandemic is the imperative safety of our students and staff and for graduate students and will help us to the protection of our mission of teaching not to ignore high consequence address the soaring demand for graduate and research. but predictable events. places and the need of our academics for researchers on their teams, without We have also found time to celebrate. — Professor Louise Richardson overcrowding our existing colleges. This year we have celebrated the centenary Vice-Chancellor of the University of Oxford The work of the college will be organised of the – belated – admission of women around broad themes critical to the future: to full membership of the University with climate change, cellular life and machine events and academic appointments. learning and AI. The highlight was the appointment of Professor Brenda Stevenson as the inaugural One of the many lessons of the holder of the newly endowed Hillary pandemic is the imperative not to ignore Rodham Clinton Chair in Women’s History. Contents high consequence but predictable events. The risk of pandemics is one example, In the pages that follow we provide more another is the growing risk of anti-microbial insight into our activities, most of which Vice-Chancellor’s welcome 1 resistance (AMR). Due largely to the are only possible because of the generous overuse of antibiotics in agriculture, we support of our alumni and friends. Championing the humanities 2 are becoming increasingly resistant to Thank you. antibiotics. Left unchecked this could herald Inspiring the next generation 3 a return to the days before penicillin was first discovered here in Oxford, when The positive impact of video games 4 minor medical treatments regularly led to infections and loss of life. Thanks to the Capturing history in the making 5 remarkable gift of £100 million from Sir Jim Ratcliffe earlier this year, the INEOS The threat of ‘Disease X’ 6 Oxford Institute will be at the vanguard Professor Louise Richardson of global research into AMR. Vice-Chancellor of the University of Oxford Recognising your support 8 Membership 10 Images © University of Oxford/John Cairns Photography, except the following: Cover © Paopano/Vadim Sadovski/Shutterstock.com. Elements of this image furnished by NASA, composite by Nadja Guggi/Messrs Dash & Dare; p. 2 © The Metropolitan Museum of Art; p. 4 © adriaticfoto/Shutterstock.com; p. 5 © Luke Jerram VICE-CHANCELLOR’S CIRCLE 2020–21 1 Being in this environment is an awe-inspiring and holistic experience that goes beyond academic benefits. Studying at Oxford, where I can conduct the most cutting-edge research in my field, means I can pursue my dreams. The scholarship made this possible for me. — Kristýna Rendlová Baillie Gifford-AHRC Scholar (Left) “The Great Abu Sa’ud Teaching Law”, Folio from a Divan of Mahmud ‘Abd-al Baqi, mid-16th century Inspiring the next The Metropolitan Museum of Art, 25.83.9 (Right) A chemistry graduate carrying out research using a Nuclear Magnetic Resonance spectrometer generation Professor Dame Carol Robinson is Professor Robinson, which works to discover numbered among such pioneers. After novel medicines using mass spectrometry. leaving school at 16, she took an unusual Professor Robinson remains at the forefront route to graduation. While working full of gas phase structural biology, a field she time as a technician, she participated in established and continues to dominate the Royal Society of Chemistry’s graduation worldwide. Her work has attracted scheme and completed her undergraduate numerous awards and prizes, including the studies. It is worthy of note that she Royal Society’s Gold Medal (A) and the subsequently was the President of the Royal Othmer Gold Medal. Professor Robinson I am extremely grateful to Society of Chemistry from 2018 to 2020. is Oxford’s first female professor of have received such generous In a record two years, Professor Robinson chemistry and currently holds the chair support. Holding an endowed completed her PhD at Cambridge University. of the Dr Lee’s Professor of Chemistry. Thereafter she took an eight-year career Recently, the endowment of her chair was Championing the humanities chair enables me to focus break to raise her three children before generously supported by a member of the on my scientific work, while undertaking a postdoctoral position Vice-Chancellor’s Circle and graduate of at Oxford under the late Professor Oxford’s Department of Chemistry. Graduate students in the humanities our research, which is often overlooked Professor Karen O’Brien, Head of the also dedicating important Sir Christopher Dobson – her mentor Inspired by their tutors while a student are pursuing their dreams thanks to but has massive social, political and Humanities Division, says: ‘Talented throughout her career and lifelong friend. time to mentoring female at Oxford, the donor wished to support the generosity of new VCC member cultural impact.’ graduate students are the lifeblood of Professor Robinson now applies the same female academics and encourage the next Baillie Gifford, an investment management a vibrant academic community, and are scientists as part of my goal mentorship principles of encouragement Kristýna Rendlová, also a scholar in generation of pioneering female chemists. firm. Nine DPhil (PhD) scholars are the professors, policy-makers and business and confidence building to her own the first cohort, is studying the pictorial to make science a more The donor gave a generous gift which, already benefiting from the donation, leaders of tomorrow. These scholarships researchers, particularly female academics representation of architecture in 15th combined with match funding from the which has been matched by the Arts and support our students at a critical period accessible career choice. working at all levels in science. and 16th-century Ottoman illustrated Endowment Challenge Fund, made the Humanities Research Council to provide in their academic development.’ manuscripts as part of her scholarship. — Professor Dame Carol Robinson Today, Professor Robinson’s research chair’s endowment possible. fully-funded scholarships to 12 scholars Kristýna explores the range of images As well as funding scholarships, is dedicated to the study of protein by 2023–2024. Dr Lee’s Professor of Chemistry The University is privileged to work with of Persianate, Byzantine, European, Baillie Gifford’s support has also established structure, function and interactions using donors who are passionate about supporting Joana Perrone is one of the first cohort Hijazi and Iraqi origin that co-existed – the Baillie Gifford Writing Partnerships mass spectrometry. In her early experiments In 2020 the University began to celebrate women in science. Their foresight and of Baillie Gifford-AHRC Scholars. She is and occasionally interacted – within Programme, which has paired more than she exploited the capability of electrospray the centenary of women’s right to generosity continue the legacy of Oxford researching femicide – the killing of women Ottoman book painting during its 250 graduate students and postdoctoral mass spectrometry to study individual matriculate and to graduate from Oxford. female pioneers and allow scientists, such because of their gender – in Brazil. She said: formative phase. Kristýna’s research researchers in the humanities with a partner proteins. Studying protein structures is This milestone has been an opportunity to as Professor Robinson, to inspire the next ‘I have developed a dataset that contains sheds new light on the processes of for regular writing meet-ups. The programme key to understanding many diseases and recognise the multiple ways in which women generation of female scientists. all femicide cases reported to the Brazilian artistic exchange and the understanding has become even more popular during to the development of treatments. In 2018, have contributed to the University and the media since January 2019, and I am of images as they were framed by diverse lockdown as researchers seek guidance and the group discovered a lipid which regulates world, as well as to commemorate those who drawing very interesting data from the cultural-historical, ideological and peer support to overcome the challenges the coupling of G-protein coupled provided the impetus for this change. These reports. I want to thank Baillie Gifford creative forces within the early modern of isolation and anxiety caused by the receptors, the target of more than 40% of pioneering figures are a source of inspiration for supporting humanities scholars and Ottoman Empire.
Load more

Recommended publications
  • Old Road Campus
    Old Road Campus 4a, 4b, 4c, U5 n o t Oxford City Centre g OLD ROAD n i d 4a, 4b, 4c, U5 a e H K O L L A D R O W AD E M I L 4,4a,4b,4c, U1X,U5 A41 42 4,4a,4b,4c,U5 Rin D 4 g R oad 6 7 1 13 3 11 C H U R C H I L L 900 D 2 R I 700, 900 V E E O x f o 5 A C rd 12 C i ty 10 C e n t re B 8 CAR PARK C 9 h u r c R F h i O l l O S H E o V s N E p L i T t DRI a VE ENTRANCE ROOSEVELT DRIVE l 900, ST2 Index 1 The Triangle Nursery 9 Old Road Campus Estates Annexe 13 Boundary Brook House Interserve Joint Research Office Kennedy Institute 2 - Research Services, Medical Sciences Division Old Road Campus Research Building 10 - Clinical Trials and Research Governance 3 New Richards Building Department of Oncology - Human Tissue Governance CRUK/MRC Oxford Institute for Radiation Oncology - Medical Sciences Division Business Development 4 NDM Research Building Institute of Biomedical Engineering Nuffield Department of Primary Care Health Sciences Target Discovery Institute Jenner Institute Medical Sciences Divisional Safety Officers Centre for Tropical Medicine and Global Health Bodleian Knowledge Centre (Library Services) Medical Sciences Division IT Services 5 Wellcome Centre for Human Genetics (WHG) Ludwig Institute for Cancer Research Structural Genomics Consortium 6 Henry Wellcome Building for Molecular Physiology Nuffield Department of Surgical Sciences Loading Bays and Delivery Offices of the Nuffield Professor of Medicine ENTRANCE VIA BUILDING 5 11 Big Data Institute A Wellcome Trust Centre for Human Genetics 7 Henry Wellcome Building for Particle Imaging
    [Show full text]
  • Astrazeneca-Oxford Vaccine Approved for Use in the U.K
    P2JW366000-6-A00100-17FFFF5178F ****** THURSDAY,DECEMBER 31,2020~VOL. CCLXXVI NO.154 WSJ.com HHHH $4.00 DJIA 30409.56 À 73.89 0.2% NASDAQ 12870.00 À 0.2% STOXX 600 400.25 g 0.3% 10-YR. TREAS. À 3/32 , yield 0.926% OIL $48.40 À $0.40 GOLD $1,891.00 À $10.50 EURO $1.2300 YEN 103.21 Deadly Attack at Airport Targets New Yemen Government U.S. IPO What’s News Market Reaches Business&Finance Record nvestorspiled into IPOs Iat a record rate in 2020, with companies raising Total $167.2 billion via 454 of- ferings on U.S. exchanges this year through Dec. 24. Few see signs of letup Few expect the euphoria after companies raise to wear off soon. A1 more than $167 billion Detenteisending in the global fight over tech taxes, despite pandemic with Franceresuming collec- tion of itsdigital-services tax BY MAUREEN FARRELL and the U.S. poised to retali- atewith tariffs.Other coun- Defying expectations,inves- tries areset to join the fray. A1 S tors piled intoinitial public of- China finished 2020 PRES feringsatarecordrateiN with a 10th consecutive TED 2020, and few expect the eu- month of expansion in its CIA phoria to wear off soon. manufacturing sector. A7 SO Companies raised $167.2 AS TheEUand China agreed TENSIONS HIGH: People fled after an explosion Wednesday at the airport in Aden, Yemen, moments after members of the billion through 454 offerings in principle on an invest- country’s newly sworn-in cabinet arrived. At least 22 people were killed, but all the members of the cabinet were safe.
    [Show full text]
  • Annual Meeting
    Volume 97 | Number 5 Volume VOLUME 97 NOVEMBER 2017 NUMBER 5 SUPPLEMENT SIXTY-SIXTH ANNUAL MEETING November 5–9, 2017 The Baltimore Convention Center | Baltimore, Maryland USA The American Journal of Tropical Medicine and Hygiene The American Journal of Tropical astmh.org ajtmh.org #TropMed17 Supplement to The American Journal of Tropical Medicine and Hygiene ASTMH FP Cover 17.indd 1-3 10/11/17 1:48 PM Welcome to TropMed17, our yearly assembly for stimulating research, clinical advances, special lectures, guests and bonus events. Our keynote speaker this year is Dr. Paul Farmer, Co-founder and Chief Strategist of Partners In Health (PIH). In addition, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, will deliver a plenary session Thursday, November 9. Other highlighted speakers include Dr. Scott O’Neill, who will deliver the Fred L. Soper Lecture; Dr. Claudio F. Lanata, the Vincenzo Marcolongo Memorial Lecture; and Dr. Jane Cardosa, the Commemorative Fund Lecture. We are pleased to announce that this year’s offerings extend beyond communicating top-rated science to direct service to the global community and a number of novel events: • Get a Shot. Give a Shot.® Through Walgreens’ Get a Shot. Give a Shot.® campaign, you can not only receive your free flu shot, but also provide a lifesaving vaccine to a child in need via the UN Foundation’s Shot@Life campaign. • Under the Net. Walk in the shoes of a young girl living in a refugee camp through the virtual reality experience presented by UN Foundation’s Nothing But Nets campaign.
    [Show full text]
  • Jenner Institute Complementary Vaccines Platform Technologies
    WHO R&D Blueprint: Janssen Vaccines – Jenner Institute complementary Vaccines Platform Technologies Janssen Vaccines: Jenner Institute: Olga Popova Prof. Sarah Gilbert Jerome Custers WHO Geneva, 21 July 2016 Background • Jenner Institute & Janssen Vaccines presented respective proposals to WHO R&D Blueprint Workshop in April 2016, and were invited to join forces for Round 2 submission • Example of alignment, coordination and partnership between public and private sector stakeholders • Understanding nature of vaccine development, established complementary end‐to‐end skills and capabilities • Long‐term, sustainable & consistent approach and funding • High‐level flexible proposal with illustrative examples • «Bona fide»: collaborative framework to be developed JOINTLY TOWARDS TANGIBLE OUTCOMES x GLOBAL PUBLIC HEALTH 2 Success factors • Available platforms and previous experience with pathogens • Ability to invest time and resources, leverage expertise, minimise opportunity costs and ensure business continuity • Appropriate and functionable operational model, speed • Lean governance, partner alignment and milestone orientation INTERNAL • Reliable & qualified partners, durable commitments • Long‐term reliable funding (min 5‐year horizon) • Resolving vaccination indemnification / liability issue • Consistency in pathogen prioritisation and defined, consistent pre‐ established endpoint commitment • Clear and accelerated / streamlined regulatory pathways, conditions & predictability of licensure EXTERNAL • Anticipated deployment plans and community
    [Show full text]
  • Sir Bryn Terfel Premieres John Rutter's 'Joseph's Carol', Dedicated to the Oxford Vaccine Team in Celebratory Concert Fr
    Sir Bryn Terfel premieres John Rutter’s ‘Joseph’s Carol’, dedicated to the Oxford vaccine team in celebratory concert from the Oxford Philharmonic Orchestra Friday 18 December 2020, 18:30 Streamed on Oxford Philharmonic Orchestra’s YouTube Channel: bit.ly/OPOVaccineTribute Elgar Chanson de Matin William Henry Monk Abide with Me Rodgers & Hammerstein You’ll Never Walk Alone John Rutter Joseph’s Carol WORLD PREMIERE John Rutter Look to the Day Handel Hallelujah Chorus Sir Bryn Terfel bass-baritone Oxford Philharmonic Orchestra Maxim Vengerov violin Choir of Merton College, Oxford John Rutter conductor Alexandra Lowe soprano Marios Papadopoulos conductor Alexander Olleson treble John Suchet presenter In recognition of the formidable work accomplished by the team of scientists at the University of Oxford on their Covid-19 vaccine, the Oxford Philharmonic Orchestra will stream a celebratory concert on Friday 18 December, recorded in the city’s historic Sheldonian Theatre. Performed by bass-baritone Sir Bryn Terfel, the short concert features the premiere of John Rutter’s Joseph’s Carol, written in tribute to the Oxford Vaccine Group, the Jenner Institute and the RECOVERY team. The words by John Rutter recount the long and weary journey of Joseph and Mary to Bethlehem before the birth of the baby Jesus, echoing the programme’s journey from struggle through to hope. Bryn Terfel also joins the Orchestra and the Choir of Merton College, Oxford, in a rousing programme from Rodgers & Hammerstein’s You’ll Never Walk Alone (with Jette Parker Young Artist Alexandra Lowe) to Handel’s Hallelujah Chorus. Sir Bryn and the Orchestra are also joined in the hymn of comfort, Abide with Me, by chorister Alexander Olleson of Christ Church Cathedral Choir, the recent winner of BBC Young Chorister Of The Year 2020.
    [Show full text]
  • Immunomodulatory Effects of the Hepatitis C Virus (HCV) Core Protein
    Immunomodulatory Effects of the Hepatitis C Virus (HCV) Core Protein By Rachel Elizabeth Owen A thesis submitted for the degree of Doctor of Philosophy at the University of London September 2003 The Edward Jenner Institute for Vaccine Research University College London ProQuest Number: U642330 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest U642330 Published by ProQuest LLC(2015). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract Hepatitis C virus establishes a persistent infection in approximately 80% of infected individuals. It is unclear why the immune system is frequently unable to mediate a response capable of controlling HCV replication. Dendritic cells (DCs) may be an extrahepatic site of viral replication and it is hypothesised that expression of the core protein within DCs may impair their functions resulting in inadequate immune responses. To investigate potential immunomodulatory effects of the core protein on DCs, replication-deficient adenoviral vectors co-expressing different versions of the core protein (full-length, truncated and a version lacking residues 125-144) with GFP were constructed. Whilst these adenoviruses were being generated, experiments were carried out with an adenoviral vector expressing all the HCV structural proteins (Ad- CE1E2).
    [Show full text]
  • 'Astrazeneca' Covid-19 Vaccine
    Medicines Law & Policy How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine By Christopher Garrison 1. Introduction. The ‘Oxford / AstraZeneca’ vaccine is one of the world’s leading hopes in the race to end the Covid-19 pandemic. Its history is not as clear, though, as it may first seem. The media reporting about the vaccine tends to focus either on the very small (non-profit, academic) Jenner Institute at Oxford University, where the vaccine was first invented, or the very large (‘Big Pharma’ firm) AstraZeneca, which is now responsible for organising its (non-profit) world-wide development, manufacture and distribution. However, examining the intellectual property (IP) path of the vaccine from invention to manufacture and distribution reveals a more complex picture that involves other important actors (with for-profit perspectives). Mindful of the very large sums of public money being used to support Covid-19 vaccine development, section 2 of this note will therefore contextualise the respective roles of the Jenner Institute, AstraZeneca and these other actors, so that their share of risk and (potential) reward in the project can be better understood. Section 3 provides comments as well as raising some important questions about what might yet be done better and what lessons can be learned for the future. 2. History of the ‘Oxford / AstraZeneca’ vaccine. 2.1 Oxford University and Oxford University Innovation Ltd. The Bayh-Dole Act (1980) was hugely influential in the United States and elsewhere in encouraging universities to commercially exploit the IP they were generating by setting up ‘technology transfer’ offices.
    [Show full text]
  • Job Description and Person Specificationselection Criteria
    Job title Senior Postdoctoral Scientist Division Medical Sciences Department Nuffield Department of Medicine, Jenner Institute Clinical Centre for Vaccinology and Translational Medicine Location (CCVTM), Old Road Campus, Headington, Oxford, OX3 7LE Grade 8: £41,526 - £49,553 per annum with a discretionary range Grade and salary to £54,131 per annum Hours Full time Contract type Fixed-term contract for 20 months, in the first instance Reporting to Professor Christine Rollier & Professor Cal MacLennan Vacancy reference 147960 Additional Position funded by US funding information Development of a Gonococcal Outer Membrane Vesicle Vaccine Research topic from Lead Optimization to Phase 1 Clinical Trial Principal Investigator Professor Christine Rollier & Professor Cal MacLennan / supervisor Project team Gonococcal Vaccine Group http://www.jenner.ac.uk/ Project web site Funding partner US funding 1. Gottlieb SL, et al. Gonococcal vaccines: public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. Vaccine 2020; 38: 4362-4373. 2. Micoli, F et al. Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella. PNAS 2018; Recent publications 115: 10428-33. 3. Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396: 467-478. 4. Marsay L, et al. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. J Infect 2015; 71: 326-37. The Role The Gonococcal Vaccine Project is based at the Jenner Institute, University of Oxford, and utilizes a novel outer membrane vesicle (OMV) technology to develop a vaccine against gonorrhoea.
    [Show full text]
  • ASTMH 65Th Annual Meeting Atlanta Marriott Marquis and Hilton Atlanta Atlanta, GA Pre-Registration List As of October 27, 2016
    ASTMH 65th Annual Meeting Atlanta Marriott Marquis and Hilton Atlanta Atlanta, GA Pre-Registration List as of October 27, 2016 *John Aaskov, PhD FRCPath Denise Abud Oladokun Adedamola Adesunloye, Queensland University of Technology Sanofi Pastuer Federal Ministry of Health(FMC) Australia USA Nigeria Neetu Abad Manfred M K Accrombessi Grace Adeya CDC Benin GHSC-PSM/Chemonics United States USA *Jane Winnie Achan, Clinical *Tochukwu Abadom MRC Unit, The Gambia Bwaka Mpia Ado Blackpool Victoria Hospital, United Gambia McKIng Consulting Corporation/ EPI Kingdom DRC Nigeria *Nicole L. Achee, PhD Dem. Republic of Congo Univ of Notre Dame *Shaymaa Abdalal, MD USA Joseph Ado-Yobo Tulane School of Public Hlth Ghana USA Salissou Adamou Bathiri Onchocerciasis & Lymphatic *Valentine Adolphe *Agatha Aboe, MBChB; DO Niger PSI Sightsavers USA Ghana *David P. Adams, PhD MPH MSc Dept of Community Medicine, Mercer Yaw Asare Afrane *Ayokunle Abogan Univ Sch of Medicine Kenya Medical Research Institute Natl Malaria Programme USA Kenya Botswana *John H. Adams, PhD Suneth Agampodi, MBBS MSc *Melanie Abongwa, MSc University of South Florida Coll of Pub Univ of Sri Lanka Iowa State University Hlth Sri Lanka USA USA *Kokila Agarwal, DRPH MBBS MPH *Ahmed Abd El Wahed Abou El Nasr, *Matthew Adams MCHIP/JHPIEGO Georg August University Goettingen Univ of Maryland Baltimore USA Germany USA Kodjovi D. Agbodjavou *Jennifer Abrahams, MD Marc Adamy Jhpiego Corp University of Miami/Jackson Memorial Medicines for Malaria Venture Togo Hospital Switzerland USA Rakesh Aggarwal, MD DM *David Addiss, MD MPH Sanjay Gandhi Postgraduate Inst of Lauren Abrams, GA Task Force for Global Hlth Med Sciences Children Without Worms USA India United States *Ahmed Adeel, MD MPH PhD *Selidji Todagbe AGNANDJI Marcelo Claudio Abril United States CERMEL Fundación Mundo Sano Gabon Argentina *Adeshina Israel Adekunle UNSW *Peter C.
    [Show full text]
  • University of Oxford Oxford OX3 7LE
    Prof Adrian Hill Centre for Clinical Vaccinology & Chief Investigator Tropical Medicine (CCVTM) The Jenner Institute Churchill Hospital University of Oxford Oxford OX3 7LE Recruitment Co-ordinator National Research Ethics Service Tel: 01865 611424 Committee: South Central Oxford A Fax: 01865 289694 Number: 17/SC/0552 Email: [email protected] PARTICIPANT INFORMATION SHEET: MERS001 A study to assess the new candidate MERS-CoV vaccine in healthy adults “A phase I study to determine the safety and immunogenicity of the candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) vaccine ChAdOx1 MERS in UK healthy adult volunteers” We would like to invite you to take part in a research study. Before you make a decision, it is important you take the time to understand why the research is being done and what it would involve. Please read the following information carefully and discuss it with friends, relatives and your General Practitioner (GP) if you wish. • Part 1 tells you the purpose of the study and what will happen to you if you take part. • Part 2 tells you more information about the conduct of the study. Please ask us if there is anything that is not clear, or if you would like more information. Take time to decide whether or not to take part. PART 1 What is the purpose of this trial? The purpose of this study is to test a new vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in healthy volunteers. MERS-CoV has been identified as one of the most worrying newly emerging outbreak diseases by many global agencies and expert groups, including the World Health Organization (WHO).
    [Show full text]
  • MALARIA VACCINES for the WORLD 2-4 May 2016, Leiden University Medical Center LUMC, Leiden, the Netherlands
    THE FOURTH INTERNATIONAL CONFERENCE ON: MALARIA VACCINES FOR THE WORLD 2-4 May 2016, Leiden University Medical Center LUMC, Leiden, The Netherlands SECOND CIRCULAR AND PROVISIONAL CONFERENCE PROGRAMME FOR MVW 2016 With more an estimated 200 million clinical cases annually, resulting in more than 580,000 deaths, malaria is not only an important global health problem but also a major factor limiting economic development in developing countries. Interventions that deploy an effective malaria vaccine are regarded as being one of the most cost-effective and reliable means to limit and ultimately eradicate the disease. In recent years, due to increased funding and research, malaria vaccine development has greatly accelerated. The MVW 2016 conference will look at different aspects of vaccine development, assessment and deployment, as well as funding and regulatory aspects of vaccine implementation and testing. The conference will also highlight research on the use of animal models and (controlled) clinical trials to study the immunological basis of protection and to identify novel candidate vaccine antigens. The MVW 2016 meeting will be of interest to scientists, physicians and other professionals from the academic, industrial/commercial and governmental/policy/regulatory sectors that have an interest in vaccine development and global health. The meeting will include talks on: Malaria vaccine candidate discovery · Novel pre-clinical screening assays/models · Vaccine immunology including system-based approaches · Correlates of protection after vaccination · Pre-erythrocytic vaccines and vaccination · Vaccines for interrupting malaria transmission: role in elimination strategies · RTS,S implementation and refinements · Vaccines against blood stage of malaria infection and multi-stage vaccines · Clinical trials of malaria vaccines controlled human malaria infections (CHMI) and field trials · Relevance and issues related to first in man trials and CHMI studies in endemic countries · Modelling and measuring long-term malaria vaccine impact.
    [Show full text]
  • Isis Insights 63
    The research commercialisation office of the University of Oxford, previously called Isis Innovation, has been renamed Oxford University Innovation All documents and other materials will be updated accordingly. In the meantime the remaining content of this Isis Innovation document is still valid. URLs beginning www.isis-innovation.com/... are automatically redirected to our new domain, www.innovation.ox.ac.uk/... Phone numbers and email addresses for individual members of staff are unchanged Email : [email protected] Ii 63 Spring 11 Issue Isis insights The latest innovations, collaborations and technology transfer Healthy futures Screening for discovery... IiContents Issue 63 Healthy futures Screening for discovery... Tackling Tuberculosis 10 Protein Superglue 26 Patient Reported Outcomes 28 03. Newsflash 18. Transformers The latest news from Isis Lightweight motor magnets 04. The Loop 20. Testing, Testing A news roundup from Oxford University Making test tube research more reliable Consulting and Isis Enterprise 22. Spring Clean 05. The Portfolio Showcasing clean-tech energy systems Investment and spin-out news 24. Fluid Thinking 06. Technology Steps Forward An acoustic separator for a wide audience The latest licence agreements 26. Protein Superglue Identifying proteins linked with diseases 08. Scouting for Success Oxford Innovation Society member Dow Chemical’s investment strategies 28. The PROs of Academic Consultancy Oxford University Consulting helping with 10. Tackling Tuberculosis healthcare A vaccine for the 21st Century 30. Above Sea Level 12. Oxford-Emergent Tuberculosis Isis Enterprise using submarine technology for Consortium Focus health screening Deeper insight into the TB vaccine partnership 16. Inside the Incubator A new initiative for Oxford software Ii is produced by Isis Innovation Ltd, the technology transfer company owned by the University of Oxford.
    [Show full text]